Table 1.
Demographics and clinical characteristics of 53 patients in active surveillance receiving resampling biopsy using the Artemis biopsy-tracking device.
| Covariate | Patient cohort (n=53) |
|---|---|
| Age1 (years) (median (IQR)) | 64 (59 – 69) |
| Race/ethnicity (n (%)) | |
| White | 44 (83%) |
| Asian | 3 (6%) |
| Hispanic | 6 (11%) |
| Time between diagnostic and 1st targeted biopsy (months) (median (IQR)) | 6 (0 – 8) |
| Time between diagnostic and 2nd targeted biopsy (months) (median (IQR)) | 17 (8 – 21) |
| Prostate volume1 (cc) (median, IQR) | 48 (36 – 60) |
| Prior prostate treatment1 (n (%)) | |
| No prior treatment | 37 (69%) |
| Transurethral resection of prostate | 3 (6%) |
| 5α-reductase inhibitor | 13 (25%) |
| PSA1 (ng/mL) (median, IQR) | 4.3 (2.2 – 6.4) |
| PSA density1 (ng/mL/cc) (median, IQR) | 0.08 (0.05 – 0.12) |
1
At time of biopsy 1